UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 329

Sortiert nach

Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

Journal of medicinal chemistry, 2012-06, Vol.55 (11), p.4896-4933

2012

Link zum Volltext

Verfügbarkeit prüfen

Structure-based Drug Metabolism Predictions for Drug Design

Chemical biology & drug design, 2010-01, Vol.75 (1), p.3-17

2010

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design

European journal of medicinal chemistry, 2012-11, Vol.57, p.441-448

2012

Link zum Volltext

Verfügbarkeit prüfen

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration

Journal of pharmaceutical sciences, 2016-02, Vol.105 (2), p.965-971

2016

Link zum Volltext

Verfügbarkeit prüfen

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

Pharmaceutical research, 2016-12, Vol.33 (12), p.3021-3030

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

PloS one, 2016-05, Vol.11 (5), p.e0155674

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics

Chemico-biological interactions, 2011-11, Vol.194 (2), p.159-167

2011

Link zum Volltext

Verfügbarkeit prüfen

In silico modeling of nonspecific binding to human liver microsomes

Drug metabolism and disposition, 2008-10, Vol.36 (10), p.2130

2008

Link zum Volltext

Verfügbarkeit prüfen

Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells

Drug metabolism and disposition, 2016-03, Vol.44 (3), p.356-364

2016

Link zum Volltext

Verfügbarkeit prüfen

A Nonprostanoid EP4 Receptor Selective Prostaglandin E2 Agonist Restores Bone Mass and Strength in Aged, Ovariectomized Rats

Journal of bone and mineral research, 2006-04, Vol.21 (4), p.565-575

2006

Link zum Volltext

Verfügbarkeit prüfen

Species independence in brain tissue binding using brain homogenates

Drug metabolism and disposition, 2011-07, Vol.39 (7), p.1270

2011

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design

ACS medicinal chemistry letters, 2011-08, Vol.2 (8), p.638-643

2011

Link zum Volltext

Verfügbarkeit prüfen

Towards a unified model of passive drug permeation I: Origins of the unstirred water layer with applications to ionic permeation

European journal of pharmaceutical sciences, 2014-02, Vol.52, p.109-124

2014

Link zum Volltext

Verfügbarkeit prüfen

In Vitro–In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein–Cannulated Monkey

Journal of pharmaceutical sciences, 2017-03, Vol.106 (3), p.898-905

2017

Link zum Volltext

Verfügbarkeit prüfen

Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators

Drug metabolism and disposition, 2014-10, Vol.42 (10), p.1599

2014

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist

Journal of medicinal chemistry, 2009-01, Vol.52 (2), p.234-237

2009

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist

Journal of medicinal chemistry, 2009-01, Vol.52 (2), p.234-237

2009

Link zum Volltext

Verfügbarkeit prüfen

Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs

Drug metabolism and disposition, 2011-12, Vol.39 (12), p.2191

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity

Journal of medicinal chemistry, 2009-05, Vol.52 (9), p.2652-2655

2009

Link zum Volltext

Verfügbarkeit prüfen

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents

ACS medicinal chemistry letters, 2012-05, Vol.3 (5), p.397-401

2012

Link zum Volltext

Verfügbarkeit prüfen

Strategic Use of Plasma and Microsome Binding To Exploit in Vitro Clearance in Early Drug Discovery

ACS medicinal chemistry letters, 2010-05, Vol.1 (2), p.50-53

2010

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity

Biochemical and biophysical research communications, 2010-04, Vol.394 (2), p.366-371

2010

Link zum Volltext

Verfügbarkeit prüfen

Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists

Bioorganic & medicinal chemistry letters, 2012-04, Vol.22 (8), p.2943-2947

2012

Link zum Volltext

Verfügbarkeit prüfen

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles

Bioorganic & medicinal chemistry letters, 2009-09, Vol.19 (18), p.5351-5354

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 329

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(281)
Mit Volltextzugriff
(294)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

Structure-based Drug Metabolism Predictions for Drug Design

Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design

Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies

Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics

In silico modeling of nonspecific binding to human liver microsomes

Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells

A Nonprostanoid EP4 Receptor Selective Prostaglandin E2 Agonist Restores Bone Mass and Strength in Aged, Ovariectomized Rats

Species independence in brain tissue binding using brain homogenates

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design

Towards a unified model of passive drug permeation I: Origins of the unstirred water layer with applications to ionic permeation

In Vitro–In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein–Cannulated Monkey

Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators

Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylamino-piperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist

Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist

Excretion, metabolism, and pharmacokinetics of CP-945,598, a selective cannabinoid receptor antagonist, in rats, mice, and dogs

Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity

Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents

Strategic Use of Plasma and Microsome Binding To Exploit in Vitro Clearance in Early Drug Discovery

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity

Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: Potent, orally-active 1,4-disubstituted imidazoles

Suchergebnisse filtern